Cargando…
Synthesis and biological evaluation of [(131)I]iodocarvedilol as a potential radiopharmaceutical for heart imaging
The optimization of the radiolabeling yield of carvedilol with iodine-131 was described. Dependence of the labeling yield of [(131)I]iodocarvedilol on the concentration of carvedilol, chloramine-T content, pH of the reaction mixture and reaction time was studied in details. Carvedilol was labeled wi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018969/ https://www.ncbi.nlm.nih.gov/pubmed/36922888 http://dx.doi.org/10.1186/s13065-023-00935-0 |
Sumario: | The optimization of the radiolabeling yield of carvedilol with iodine-131 was described. Dependence of the labeling yield of [(131)I]iodocarvedilol on the concentration of carvedilol, chloramine-T content, pH of the reaction mixture and reaction time was studied in details. Carvedilol was labeled with iodine-131 at pH 6 with a labeling yield of 92.6 ± 2.77% by using 100 µg carvedilol, 200 µg chloramin-T (CAT) and 30 min reaction time. The formed [(131)I]iodocarvedilol was nearly stable for a time up to one day. Biodistribution of [(131)I]iodocarvedilol was investigated in experimental animals. [(131/123)I]iodocarvedilol was located in the heart with a concentration of 19.6 ± 0.41% of the injected dose at 60 min post injection. It has a high heart uptake and heart to liver ratio, both of which are beneficial for high-quality SPECT (single-photon emission computerized tomography) myocardial imaging. [(131/123)I]iodocarvedilol solve most the drawbacks of the FDA (Food and Drug Administration) approved (99m)Tc-sestamibi. |
---|